Spots Global Cancer Trial Database for autologous stem cell transplantation
Every month we try and update this database with for autologous stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | NCT00144807 | Diffuse Large C... | rituximab doxorubicin cyclophosphamid... autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia | NCT02844361 | Waldenström Mac... | autologous stem... conventional ch... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | NCT01341262 | Multiple Myelom... | Thalidomide Dexamethasone Zoledronic acid Cyclophosphamid... Melphalan | 18 Years - 65 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | NCT00075608 | Multiple Myelom... Plasma Cell Neo... | filgrastim melphalan autologous stem... stem cell infus... | 18 Years - 65 Years | Boston Medical Center | |
| Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma | NCT05755828 | B-cell Lymphoma | ASCT+CAR-T Cell... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | NCT01361191 | Diffuse Large B... Follicular Grad... | R-MEGACHOP | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis | NCT00424489 | Myasthenia Grav... | Hematopoietic S... Cyclophosphamid... ATG (rabbit) Mesna Methylprednisol... G-CSF | 15 Years - 65 Years | Northwestern University | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology | NCT04703985 | Lymphoma Myeloma | Enteral Nutriti... | 18 Years - | University Hospital, Bordeaux | |
| ASCT With Nivolumab in Patients With Multiple Myeloma | NCT03292263 | Multiple Myelom... | Melphalan Nivolumab Autologous Stem... | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | NCT00344526 | Primary Systemi... | Melphalan Dexamethasone Autologous stem... | 18 Years - 70 Years | University Hospital, Limoges | |
| Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | NCT03896737 | Multiple Myelom... | Daratumumab plu... Velcade Thalido... | 18 Years - 65 Years | Stichting European Myeloma Network | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | NCT02756728 | Multiple Myelom... | BI-505 High dose melph... Autologous stem... | 18 Years - 70 Years | BioInvent International AB | |
| Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room | NCT06286241 | Multiple Myelom... | 18 Years - 65 Years | Siriraj Hospital | ||
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | NCT04628026 | Acute Myeloid L... Myelodysplastic... | Venetoclax Placebo Standard chemot... Autologous stem... Allogeneic stem... | 18 Years - | University of Ulm | |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | NCT00984828 | Multiple Myelom... | velcade | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | NCT05367856 | T Cell Lymphoma | Chidamide combi... | 18 Years - 65 Years | Ruijin Hospital | |
| Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients | NCT03042429 | Neuroblastoma | Cycles N8, N5 a... Cycles N5 and N... | 6 Months - 21 Years | University of Cologne | |
| Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years | NCT01671826 | Newly Diagnosed... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma | NCT00384553 | Non-Hodgkin's L... | Rituximab DHAP TEC autologous stem... | 18 Years - 65 Years | University of Magdeburg | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| ASCT With Nivolumab in Patients With Multiple Myeloma | NCT03292263 | Multiple Myelom... | Melphalan Nivolumab Autologous Stem... | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | NCT01142232 | Multiple Myelom... | Lenalidomide pl... Lenalidomide ma... | 18 Years - | Indiana University | |
| Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | NCT02843074 | Multiple Myelom... | elotuzumab Lenalidomide Dexamethasone autologous stem... | 18 Years - | SCRI Development Innovations, LLC | |
| "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival | NCT01171430 | Multiple Myelom... | Whole Body Dyna... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | NCT02415413 | Smoldering Mult... | carfilzomib Lenalidomide Dexamethasone Melphalan | 18 Years - 70 Years | PETHEMA Foundation | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL | NCT03042585 | Relapsed Non Ho... Refractory Non-... | Total body irra... | 18 Years - | Loyola University | |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | NCT00984828 | Multiple Myelom... | velcade | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation | NCT00348959 | Hematological M... | 'Open Window' P... | 16 Years - | St. James's Hospital, Ireland | |
| MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | NCT02399189 | Primary Central... | R-MT followed b... | 18 Years - 65 Years | Peking University | |
| Zevalin-beam for Aggressive Lymphoma | NCT00491491 | Non-Hodgkin's L... | ibritumomab tiu... BEAM chemothera... | 18 Years - 70 Years | Sheba Medical Center | |
| CT Antigen TCR-Engineered T Cells for Myeloma | NCT01892293 | Multiple Myelom... | Treatment with ... | 18 Years - 80 Years | Adaptimmune | |
| Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | NCT04483739 | Multiple Myelom... | Carfilzomib Len... Isatuximab Carf... | 18 Years - 70 Years | Stichting European Myeloma Network | |
| Frontline of ASCT in High-risk DLBCL | NCT05831865 | Diffuse Large B... | 18 Years - 70 Years | Peking University People's Hospital | ||
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia | NCT02844361 | Waldenström Mac... | autologous stem... conventional ch... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | NCT00398411 | Hodgkin Disease Non-Hodgkin Lym... Multiple Myelom... Bacteremia | moxifloxacin placebo | 18 Years - 75 Years | University of Cologne | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Maintenance Therapy Using Lenalidomide in Myeloma | NCT00430365 | Myeloma | lenalidomide placebo | 18 Years - 65 Years | University Hospital, Toulouse | |
| Pedometer Activity Monitoring After ASCT | NCT03238599 | Lymphoma Myeloma High-dose Chemo... Autologous Stem... | Pedometer-based... | 18 Years - 65 Years | Insel Gruppe AG, University Hospital Bern | |
| Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients | NCT02981199 | Microtransplant... Autologous Stem... Multiple Myelom... | stem cell trans... | 18 Years - 65 Years | Beijing Chao Yang Hospital | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | NCT02415413 | Smoldering Mult... | carfilzomib Lenalidomide Dexamethasone Melphalan | 18 Years - 70 Years | PETHEMA Foundation | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. | NCT05835726 | Multiple Myelom... Daratumumab Autologous Stem... Leukapheresis | Daratumumab | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival | NCT01171430 | Multiple Myelom... | Whole Body Dyna... | 18 Years - 70 Years | Assistance Publique - Hôpitaux de Paris | |
| Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas | NCT00152126 | Neuroblastoma Central Nervous... Lymphomas Wilms Tumor | Stem Cell Trans... Busulfan, Melph... | - 25 Years | St. Jude Children's Research Hospital | |
| Redirected Auto T Cells for Advanced Myeloma | NCT01352286 | Multiple Myelom... | Autologous Gene... | 18 Years - 80 Years | GlaxoSmithKline | |
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | NCT01927718 | Myeloma | Thalidomide Lenalidomide Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | NCT01278602 | Diffuse Large B... | R-ESHAP | 18 Years - 65 Years | Fudan University | |
| Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) | NCT01926665 | Lymphoma | Carfilzomib Dexamethasone | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Music Therapy on Nausea and Pain for Autologous Stem Cell | NCT01487031 | Multiple Myelom... Non-Hodgkin Lym... Hodgkin Lymphom... | Music Therapy No music therap... | 18 Years - | Case Comprehensive Cancer Center | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Lonquek for Autologous Stem Cell Mobilization | NCT02488382 | Lymphoma Multiple Myelom... | Lonquek | 18 Years - 65 Years | Sheba Medical Center | |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) | NCT02008006 | Follicular Lymp... | BeEAM | 18 Years - 65 Years | Centre Leon Berard | |
| Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis | NCT00424489 | Myasthenia Grav... | Hematopoietic S... Cyclophosphamid... ATG (rabbit) Mesna Methylprednisol... G-CSF | 15 Years - 65 Years | Northwestern University | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | NCT00169130 | Lymphoma, Large... | doxorubicin cyclophosphamid... Autologous stem... | 18 Years - 60 Years | Lymphoma Study Association | |
| Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | NCT00417911 | Multiple Myelom... | bortezomib | 18 Years - | Nordic Myeloma Study Group | |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) | NCT02008006 | Follicular Lymp... | BeEAM | 18 Years - 65 Years | Centre Leon Berard | |
| Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. | NCT02006225 | Autologous Stem... | Plerixafor | - 30 Years | Tel-Aviv Sourasky Medical Center | |
| CIBMTR Research Database | NCT01166009 | Autologous Stem... Allogeneic Stem... Solid Tumors Blood Cancers CAR-T Gene Therapy Non-malignant D... | - | Center for International Blood and Marrow Transplant Research | ||
| The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma | NCT04489264 | Peripheral T Ce... | Transplant, Aut... | 18 Years - 65 Years | Peking University | |
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | NCT00398411 | Hodgkin Disease Non-Hodgkin Lym... Multiple Myelom... Bacteremia | moxifloxacin placebo | 18 Years - 75 Years | University of Cologne | |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02570542 | Diffuse Large B... Relapsed Diffus... Refractory Diff... | leukapheresis Plerixafor carmustine, eto... Autologous Stem... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT03283111 | Lymphoma | autologous stem... | 18 Years - 65 Years | Peking University | |
| IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma | NCT01333605 | Hodgkin Lymphom... | IGEV | 18 Years - 65 Years | Fudan University | |
| Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era | NCT03663894 | Patient's Outco... | 18 Years - | Hospices Civils de Lyon | ||
| MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | NCT02399189 | Primary Central... | R-MT followed b... | 18 Years - 65 Years | Peking University | |
| Effect of Vitamin C in Autologous Stem Cell Transplantations | NCT03964688 | Myeloma Multipl... Lymphoma | Vitamin C Placebos | 18 Years - | Maastricht University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
